The synergistic or combined effects by co-delivering anti-cancer drugs and siRNAs have also confirmed that Gal-DOX/siRNA-Ls had stronger tumor growth inhibition activity than DOX/siRNA-Ls and free DOX. The gene discussed is GAL; the disease is neoplasm.